DCT

2:26-cv-09805

Shionogi Inc v. Azurity Pharma Inc

Log In
Key Events
Complaint
complaint Intelligence

I. Executive Summary and Procedural Information

  • Parties & Counsel:
  • Case Identification: 2:26-cv-09805, D.N.J., 08/03/2026
  • Venue Allegations: Plaintiff alleges venue is proper in the District of New Jersey because Defendant Azurity has a regular and established place of business in the state and has committed acts of infringement there, including the submission of the New Drug Application at issue. Venue is also asserted based on the New Jersey presence of Defendant Slayback, which Plaintiff characterizes as an agent or alter ego of Azurity.
  • Core Dispute: Plaintiff alleges that Defendants' filing of a 505(b)(2) New Drug Application (NDA) with the FDA to market a generic oral formulation of edaravone constitutes an act of patent infringement under the Hatch-Waxman Act.
  • Technical Context: The technology concerns a pharmaceutical formulation for treating Amyotrophic Lateral Sclerosis (ALS), a fatal neurodegenerative disease, by providing the drug edaravone in an oral suspension, which is easier for patients to administer than previous intravenous methods.
  • Key Procedural History: This action was triggered by Defendants' submission of NDA No. 221059 and a corresponding Paragraph IV certification notice letter, challenging U.S. Patent No. 12,599,586. Plaintiff Shionogi recently acquired the assets related to the brand-name drug, RADICAVA ORS®, from Tanabe Pharma Corporation on April 1, 2026. The complaint notes numerous other pending patent infringement actions in the district related to RADICAVA ORS®. The FDA has granted RADICAVA ORS® an Orphan Drug Exclusivity period set to expire on May 12, 2029.

Case Timeline

Date Event
2018-11-02 '586 Patent Priority Date
2022-05-12 FDA approves Shionogi's RADICAVA ORS® (NDA No. 215446)
2023-09-27 Azurity announces acquisition of Slayback Pharma
2024-03-28 FDA grants Orphan Drug Exclusivity for RADICAVA ORS®
2026-04-01 Shionogi acquires RADICAVA ORS® business from Tanabe Pharma
2026-04-14 '586 Patent Issues
2026-06-16 Date of Defendants' Notice Letter
2026-08-03 Complaint Filing Date

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 12,599,586 - "Edaravone suspension for oral administration"

  • Patent Identification: U.S. Patent No. 12,599,586 ("Edaravone suspension for oral administration"), issued April 14, 2026 (the "'586 Patent").

The Invention Explained

  • Problem Addressed: The patent addresses the challenges of administering medication to patients with Amyotrophic Lateral Sclerosis (ALS) '586 Patent, col. 1:52-54 ALS patients often develop difficulty swallowing (dysphagia), making solid oral dosage forms like tablets difficult to take '586 Patent, col. 23:48-52 While intravenous (IV) injections are an alternative, they are burdensome for patients and caregivers '586 Patent, col. 25:1-4 Furthermore, creating an oral drug with bioavailability equivalent to an IV version is technically difficult due to the low water solubility of edaravone and metabolic effects '586 Patent, col. 23:40-47
  • The Patented Solution: The '586 Patent discloses an oral suspension that keeps solid particles of edaravone uniformly dispersed in water using a specific type of excipient called a "dispersant" '586 Patent, abstract '586 Patent, col. 1:14-17 This formulation is designed to be easily swallowed, maintain a consistent dosage, and allow for rapid redispersion even after settling '586 Patent, col. 3:5-15 By controlling the particle size and using a dispersant, the invention achieves bioavailability comparable to an IV injection at a much lower oral dose '586 Patent, col. 7:55-65
  • Technical Importance: The invention provides an oral administration route for edaravone that significantly reduces the patient and caregiver burden associated with IV infusions, improving quality of life for those with ALS Compl. ¶¶11-12

Key Claims at a Glance

  • The complaint asserts infringement of one or more claims, including at least independent claim 1 Compl. ¶59
  • The essential elements of independent claim 1 are:
    • An edaravone suspension for human oral administration comprising water, edaravone particles dispersed in the water, and a dispersant.
    • The dispersant maintains the edaravone particles in a "solid particle state."
    • The suspension is prepared by mixing edaravone particles of a specific size distribution (D50 particle size of 10-50 µm; D90 of 50-200 µm) with the water and dispersant.
    • The edaravone particles must have a dissolution rate of 80% or more after 30 minutes in a specified test. '586 Patent, col. 25:61 - col. 27:4
  • The complaint reserves the right to assert other claims, which may include dependent claims.

III. The Accused Instrumentality

Product Identification

  • Defendants' proposed "edaravone oral formulation '105 mg / 5 mL'," which is the subject of 505(b)(2) New Drug Application (NDA) No. 221059 Compl. ¶43 Compl. ¶45

Functionality and Market Context

  • The accused product is an oral formulation of the drug edaravone intended for the treatment of ALS Compl. ¶25 The complaint alleges it is a "proposed generic copy of RADICAVA ORS®" Compl. ¶47 Defendants are seeking FDA approval to manufacture, use, and sell this product in the United States prior to the expiration of the '586 Patent Compl. ¶2 Compl. ¶47 A key allegation is that Defendants' own notice letter characterized their product as an "edaravone solution" Compl. ¶51

No probative visual evidence provided in complaint.

IV. Analysis of Infringement Allegations

The complaint, filed under the Hatch-Waxman Act, bases its infringement allegations on a review of confidential materials from Defendants' NDA No. 221059 Compl. ¶56 It does not provide a detailed, element-by-element infringement analysis but asserts that the proposed product will infringe one or more claims, including claim 1, either literally or under the doctrine of equivalents Compl. ¶59

'586 Patent Infringement Allegations

Claim Element (from Independent Claim 1) Alleged Infringing Functionality Complaint Citation Patent Citation
An edaravone suspension for human oral administration, comprising: water; edaravone particles comprising edaravone and dispersed in the water; and a dispersant...maintains the edaravone particles in a solid particle state... The complaint alleges Defendants' proposed product is an "edaravone oral formulation" Compl. ¶43 that, upon information and belief, infringes claim 1 Compl. ¶59 ¶59 col. 25:61-67
...prepared by a process comprising mixing the edaravone particles having a D50 particle size in a range of 10 µm to 50 µm and a D90 particle size in a range of 50 µm to 200 µm... The complaint does not contain specific allegations regarding the particle size of Defendants' product but alleges infringement based on review of the confidential NDA Compl. ¶56 ¶56 col. 26:65-27:2
...and the edaravone particles have a dissolution rate of 80% or more 30 minutes after a start of a dissolution test according to Dissolution Test Method 2 of Japanese Pharmacopoeia. The complaint does not contain specific allegations regarding the dissolution rate of Defendants' product but alleges infringement based on review of the confidential NDA Compl. ¶56 ¶56 col. 27:2-4
  • Identified Points of Contention:
    • Scope Question: A potential dispute centers on the distinction between a "suspension" and a "solution." The '586 Patent claims a "suspension" in which edaravone exists in a "solid particle state" '586 Patent, claim 1 The complaint notes that Defendants' notice letter allegedly describes their product as a "solution" Compl. ¶51 This raises the question of whether a product characterized as a solution, where the active ingredient is fully dissolved, can infringe claims directed to a suspension of solid particles.
    • Technical Questions: The complaint does not provide specific data from the NDA regarding the accused product's formulation. Therefore, key questions will revolve around whether Plaintiff can prove that Defendants' product meets the explicit numerical limitations of claim 1. This includes:
      • What evidence does the confidential NDA contain regarding the particle size distribution (D50 and D90 values) of the edaravone in Defendants' formulation?
      • Does the accused product use a "dispersant" as defined in the patent, and does it meet the functional requirements for that term?
      • What is the "dissolution rate" of the edaravone in Defendants' product when measured according to the test specified in the claim?

V. Key Claim Terms for Construction

  • The Term: "suspension"

  • Context and Importance: This term is critical because the complaint alleges that Defendants have described their own product as a "solution" Compl. ¶51 The distinction between a suspension (undissolved solid particles in a liquid) and a solution (solute fully dissolved in a solvent) is fundamental in pharmaceutical science. If the accused product is a true solution, it may not literally infringe a claim directed to a suspension.

  • Intrinsic Evidence for Interpretation:

    • Evidence for a Broader Interpretation: The patent does not provide an explicit definition that would broaden the conventional meaning of "suspension."
    • Evidence for a Narrower Interpretation: The language of claim 1 itself provides strong support for a narrow, conventional definition. It explicitly requires "edaravone particles" that are maintained "in a solid particle state" '586 Patent, col. 26:65-67 The specification consistently refers to "edaravone particles" and their "particle sizes," which implies the presence of undissolved solid material '586 Patent, col. 3:20-23

  • The Term: "dispersant"

  • Context and Importance: The dispersant is a key component required to keep the edaravone particles suspended. The scope of this term will determine which excipients in the accused product could satisfy this claim element. Practitioners may focus on this term because the patent provides both a general functional definition and specific quantitative tests.

  • Intrinsic Evidence for Interpretation:

    • Evidence for a Broader Interpretation: The specification states that "any dispersant that allows the edaravone particles to be well dispersed in water without causing the edaravone particles to form secondary agglomerates may be used" '586 Patent, col. 3:16-20 This language could support a broad interpretation covering any substance that performs this general function.
    • Evidence for a Narrower Interpretation: The specification also describes specific, measurable criteria for a suitable dispersant, such as exhibiting a "transmission scattering light intensity of 1% or more" or a "contact angle of 80 degrees or less" under defined test conditions '586 Patent, col. 3:21-25 '586 Patent, col. 3:45-47 A party could argue that these quantitative tests define and limit the scope of the term "dispersant" to only those substances that meet these specific physical properties.

VI. Other Allegations

  • Indirect Infringement: The complaint alleges that Defendants' commercialization of their product will induce and contribute to the infringement of the '586 Patent Compl. ¶65 Compl., Prayer B In the context of a Hatch-Waxman case, this allegation is typically based on the argument that by seeking approval for a patented use, the generic applicant intends for its product to be used in an infringing manner, as will be directed by the product's label.
  • Willful Infringement: While the complaint does not use the word "willful," it alleges that Defendants had "actual and constructive notice" of the '586 Patent prior to filing their NDA Compl. ¶63 It also seeks a declaration that the case is "exceptional" and an award of attorneys' fees pursuant to 35 U.S.C. § 285 Compl., Prayer E, which are remedies often associated with findings of willful infringement or other litigation misconduct.

VII. Analyst's Conclusion: Key Questions for the Case

  • A core issue will be one of product form: does Defendants' proposed "edaravone oral formulation," which the complaint alleges was characterized as a "solution" Compl. ¶51, meet the claim limitation of a "suspension" requiring edaravone to be maintained "in a solid particle state" '586 Patent, claim 1?
  • A key evidentiary question will be one of parametric infringement: can the Plaintiff prove, using evidence from Defendants' confidential NDA, that the accused product meets the specific, quantitative claim limitations for edaravone particle size (D50 and D90 values) and dissolution rate?
  • A central question of claim construction will be the definition of "dispersant." The court's decision on whether to adopt the broad functional language or the narrower, quantitative tests described in the specification '586 Patent, col. 3:21-47 could be dispositive for the infringement analysis.
Loading Complaint